menu
    • menu
    [{"orgOrder":0,"company":"Phillips - Medisize","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline\u00ae Autogel\u00ae \/ Somatuline\u00ae Depot (lanreotide) Designed to Improve Patient Experience","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Lanreotide Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Phillips - Medisize","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phillips - Medisize \/ Phillips-Medisize","highestDevelopmentStatusID":"12","companyTruncated":"Phillips - Medisize \/ Phillips-Medisize"}]

    Find Clinical Drug Pipeline Developments & Deals by Phillips - Medisize

    Menu

    Phillips - Medisize

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Phillips - Medisize

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Phillips - Medisize

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanreotide Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Ipsen

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline® Autogel® / Somatu...

                            Details : Ipsen’s extensive experience with Somatuline Autogel / Somatuline Depot has offered deep insights into the challenges of living with gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome or acromegaly.

                            Brand Name : Somatuline Autogel

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 16, 2022

                            Lead Product(s) : Lanreotide Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Ipsen

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth